European Commission approves expanded use of Merck's Keytruda in bladder cancer. Sanofi & Lilly announce data from phase III studies on pipeline...

Eli Lilly stock boasts both defensive and growth characteristics

Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

DKS posts robust second-quarter fiscal 2024 results, thanks to the solid execution of its strategic efforts.

DLTR posts soft second-quarter fiscal 2024 results due to a challenging macro backdrop.

DLTR posts soft second-quarter fiscal 2024 results due to a challenging macro backdrop.

RH's second-quarter fiscal 2024 results reflect strong demand despite a challenging housing market.